People In Health Care
Dr Marina Berbic
Genetic Pathologist and Deputy Director of Genetics
Douglass Hanly Moir Pathology
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
Australian Health Journal spoke to Dr Berbic about her career and being a genetic pathologist. She started as a junior doctor in obstetrics and gynaecology after completing a medical degree, though never thought about specialising in pathology. The more she learned about genetic pathology, the more intrigued she became, realising that this specialty aligned with both her strengths and interests.
Dr Berbic has always been interested in science, technology, and innovation. She first studied for a Bachelor of Medical Science degree, followed by a Master’s in Reproductive Health and Human Genetics and then a PhD in Reproductive Medicine. Dr Berbic has long-standing academic interests, both from a research and teaching perspective. She continues to be involved in medical education at the University of New South Wales in her role as an Adjunct Senior Lecturer.
After completing her specialist training and attaining fellowship of the Royal College of Pathologists of Australasia, she commenced her role as a genetic pathologist at Douglass Hanly Moir and later became the Deputy Director of Genetics department. Her role involves providing clinical governance and medical leadership that governs all aspects of medical testing in genetics.
In this interview, Dr Berbic talks about the exciting area of genetic pathology impacting multiple areas of medicine including paediatrics, obstetrics and gynaecology, cardiology, neurology, oncology, and other fields.
The results of genetic testing have a potential impact on the patient’s diagnosis, the decisions that couples may take when they’re making reproductive decisions, and also have predictive implications. The testing results may influence therapy, selection, or patient management and may have far ranging impact on the individual as well as their family.
You Might also like
-
Clinical trial site in primary care setting open for novel therapies in psychiatry
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
-
ACN National Nursing Forum 2019
The Australian College of Nursing National Nursing Forum was held in Hobart Tasmania in August 2019.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.